0.9000
13-February-25 16:45:00
15 minutes delayed
Stocks
+0.0101
+1.13%
Today's range
0.8700 - 0.9150
ISIN
N/A
Source
NASDAQ
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
18 Oct 2023 08:30:00 By Nasdaq GlobeNewswire
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
06 Oct 2023 08:30:00 By Nasdaq GlobeNewswire